Literature DB >> 19207420

Identification of allosteric PIF-pocket ligands for PDK1 using NMR-based fragment screening and 1H-15N TROSY experiments.

Brian J Stockman1, Michael Kothe, Darcy Kohls, Laura Weibley, Brendan J Connolly, Alissa L Sheils, Qing Cao, Alan C Cheng, Lily Yang, Ajith V Kamath, Yuan-Hua Ding, Maura E Charlton.   

Abstract

Aberrant activation of the phosphoinositide 3-kinase pathway because of genetic mutations of essential signalling proteins has been associated with human diseases including cancer and diabetes. The pivotal role of 3-phosphoinositide-dependent kinase-1 in the PI3K signalling cascade has made it an attractive target for therapeutic intervention. The N-terminal lobe of the 3-phosphoinositide-dependent kinase-1 catalytic domain contains a docking site which recognizes the non-catalytic C-terminal hydrophobic motifs of certain substrate kinases. The binding of substrate in this so-called PDK1 Interacting Fragment pocket allows interaction with 3-phosphoinositide-dependent kinase-1 and enhanced phosphorylation of downstream kinases. NMR spectroscopy was used to a screen 3-phosphoinositide-dependent kinase-1 domain construct against a library of chemically diverse fragments in order to identify small, ligand-efficient fragments that might interact at either the ATP site or the allosteric PDK1 Interacting Fragment pocket. While majority of the fragment hits were determined to be ATP-site binders, several fragments appeared to interact with the PDK1 Interacting Fragment pocket. Ligand-induced changes in 1H-15N TROSY spectra acquired using uniformly 15N-enriched PDK1 provided evidence to distinguish ATP-site from PDK1 Interacting Fragment-site binding. Caliper assay data and 19F NMR assay data on the PDK1 Interacting Fragment pocket fragments and structurally related compounds identified them as potential allosteric activators of PDK1 function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19207420     DOI: 10.1111/j.1747-0285.2008.00768.x

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  18 in total

1.  Isotope labeling in insect cells.

Authors:  Krishna Saxena; Arpana Dutta; Judith Klein-Seetharaman; Harald Schwalbe
Journal:  Methods Mol Biol       Date:  2012

2.  A small-molecule mimic of a peptide docking motif inhibits the protein kinase PDK1.

Authors:  T Justin Rettenmaier; Jack D Sadowsky; Nathan D Thomsen; Steven C Chen; Allison K Doak; Michelle R Arkin; James A Wells
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-17       Impact factor: 11.205

Review 3.  Small-molecule inhibitors of protein-protein interactions: progressing toward the reality.

Authors:  Michelle R Arkin; Yinyan Tang; James A Wells
Journal:  Chem Biol       Date:  2014-09-18

4.  Discovery of PDK1 kinase inhibitors with a novel mechanism of action by ultrahigh throughput screening.

Authors:  Ekaterina V Bobkova; Michael J Weber; Zangwei Xu; Yan-Ling Zhang; Joon Jung; Peter Blume-Jensen; Alan Northrup; Priya Kunapuli; Jannik N Andersen; Ilona Kariv
Journal:  J Biol Chem       Date:  2010-04-12       Impact factor: 5.157

5.  Multiple implications of 3-phosphoinositide-dependent protein kinase 1 in human cancer.

Authors:  Yuwen Li; Keum-Jin Yang; Jongsun Park
Journal:  World J Biol Chem       Date:  2010-08-26

6.  Discovery of a Potent Allosteric Kinase Modulator by Combining Computational and Synthetic Methods.

Authors:  Edwin Kroon; Jörg O Schulze; Evelyn Süß; Carlos J Camacho; Ricardo M Biondi; Alexander Dömling
Journal:  Angew Chem Int Ed Engl       Date:  2015-09-04       Impact factor: 15.336

Review 7.  Expanding the number of 'druggable' targets: non-enzymes and protein-protein interactions.

Authors:  Leah N Makley; Jason E Gestwicki
Journal:  Chem Biol Drug Des       Date:  2013-01       Impact factor: 2.817

Review 8.  PDK1 inhibitors.

Authors:  Elisa Barile; Surya K De; Maurizio Pellecchia
Journal:  Pharm Pat Anal       Date:  2012-05

9.  Development and NMR validation of minimal pharmacophore hypotheses for the generation of fragment libraries enriched in heparanase inhibitors.

Authors:  Rafael Gozalbes; Silvia Mosulén; Rodrigo J Carbajo; Antonio Pineda-Lucena
Journal:  J Comput Aided Mol Des       Date:  2009-05-07       Impact factor: 3.686

10.  Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR).

Authors:  Juan M García-Martínez; Jennifer Moran; Rosemary G Clarke; Alex Gray; Sabina C Cosulich; Christine M Chresta; Dario R Alessi
Journal:  Biochem J       Date:  2009-06-12       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.